跳至主要内容
临床试验/CTRI/2010/091/000632
CTRI/2010/091/000632已完成4 期

Efficacy and tolerability of Bisoprolol in patients with newly diagnosed Stage I essential hypertension.

Merck Serono Merck Ltd0 个研究点目标入组 2,000 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
2,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1 Newly diagnosed JNC 7 Stage I essential hypertension
  • 2 Patient advised CONCOR (Bisoprolol)
  • 3 No other clinically significant co-morbidities

排除标准

  • 1 Any contraindications to CONCOR
  • 2 Uncontrolled diabetes (Any ongoing symptoms or complication related to Diabetes)
  • 3 Females in childbearing age not willing to use a reliable mean of contraception
  • 4 Confirmed diagnosis of any CVD except Hypertension

研究者

相似试验